Tag Archives: TBPH

Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Average Rating of “Hold” from Analysts

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) have received a consensus rating of “Hold” from the nine research firms that are presently covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $18.33.

TBPH has been the topic of several analyst reports. Needham & Company LLC cut their price target on Theravance Biopharma....More>>>

Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Average Rating of “Hold” from Analysts

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) have received a consensus rating of “Hold” from the nine research firms that are presently covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $18.33.

TBPH has been the topic of several analyst reports. Needham & Company LLC cut their price target on Theravance Biopharma....More>>>

Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Average Rating of “Hold” from Analysts

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) have received a consensus rating of “Hold” from the nine research firms that are presently covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $18.33.

TBPH has been the topic of several analyst reports. Needham & Company LLC cut their price target on Theravance Biopharma....More>>>

Best Biotech Stocks For 2023

Alliancebernstein L.P. raised its stake in shares of Vericel Co. (NASDAQ:VCEL) by 74.3% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 102,380 shares of the biotechnology company’s stock after purchasing an additional 43,630 shares during the quarter. Alliancebernstein L.P. owned 0.22% of Vericel worth $5,375,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently made changes to their positions in the company. Royal....More>>>

Hot Low Price Stocks To Watch For 2023

Betting on bargain stocks that have a low price-to-earnings (P/E) ratio is a convenient and common investment approach. The perception is that the lower the P/E, the higher is the value of the stock. This inference is drawn on the simple logic that a stock’s current market price does not justify (is not equivalent to) its higher earnings and therefore has room to run.

Naturally, there are very few investors who pay attention to stocks with an increasing P/E. But this often-overlooked trend can prove useful in finding great stocks. Let’s dig a little deeper.

Why Stocks....More>>>